Selank Compound

Sources / the literature

Selank references: every source, in full

The peer-reviewed studies behind every cited claim on this site, numbered to match the [N] markers throughout.

Back to the researchEffects & safety

About these references

Every numbered marker on this site maps to one of the studies below. The Selank evidence base is concentrated in Russian research groups and Russian-language journals (English abstracts available), which is the single biggest caveat to keep in mind when reading any Selank claim. Where a DOI exists it is listed; every entry links to its PubMed record.

  1. Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018;25(10):914-923. ↗
  2. Zozulya AA, Kost NV, Sokolov OYu, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. 2001;131(4):315-317. ↗
  3. Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. ↗
  4. Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. ↗
  5. Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75. ↗
  6. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic medication (selank) in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. ↗
  7. Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017;2017:5091027. ↗
  8. Kolik LG, Nadorova AV, Kozlovskaya MM, et al. Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation. Bull Exp Biol Med. 2014;157(1):52-55. ↗
  9. Kolik LG, Nadorova AV, Seredenin SB, et al. Selank Inhibits Ethanol-Induced Hyperlocomotion and Manifestation of Behavioral Sensitization in DBA/2 Mice. Bull Exp Biol Med. 2016;162(1):56-59. ↗
  10. Kolik LG, Nadorova AV, Antipova TA, et al. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment in Rats. Bull Exp Biol Med. 2019;167(5):641-644. ↗
  11. Konstantinopolsky MA, Chernyakova IV, Kolik LG, et al. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal Syndrome. Bull Exp Biol Med. 2022;173(6):730-733. ↗
  12. Mukhina AY, Mishina ES, Bobyntsev II, et al. Morphological Changes in the Large Intestine of Rats Subjected to Chronic Restraint Stress and Selank Administration. Bull Exp Biol Med. 2020;169(2):281-285. ↗
  13. Sarkisova KIu, Kozlovskii II, Kozlovskaia MM, et al. Effects of heptapeptide selank on genetically-based and situation-provoked anxiety in rats. Zh Vyssh Nerv Deiat Im I P Pavlova. 2008;58(2):226-237. ↗
  14. Kolomin TA, Agapova TIu, Agniullin IaV, et al. Transcriptome alteration in the hippocampus under the treatment with the tuftsin analog Selank. Zh Vyssh Nerv Deiat Im I P Pavlova. 2013;63(3):365-374. ↗
  15. Vasil'eva EV, Kondrakhin EA, Salimov RM, et al. Comparison of Pharmacological Effects of Heptapeptide Selank After Intranasal and Intraperitoneal Administration. Eksp Klin Farmakol. 2016;79(9):3-11. ↗
  16. Medvedev VE, Tereshchenko ON, Kost NV, et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33-40. ↗
  17. Fomenko EV, Bobyntsev II, Kryukov AA, et al. Effect of Selank on Functional State of Rat Hepatocytes under Conditions of Immobilization Stress. Bull Exp Biol Med. 2017;163(4):415-418. ↗
  18. Narkevich VB, Kudrin VS, Klodt PM, et al. Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/c and C57Bl/6 mice. Eksp Klin Farmakol. 2008;71(5):8-12. ↗
  19. Leonidovna YA, Aleksandrovna SM, Aleksandrovna TA, et al. The Influence of Selank on the Level of Cytokines Under the Conditions of Stressogenic Effect. Curr Rev Clin Exp Pharmacol. 2021;16(2):162-167. ↗
  20. Ershov FI, Uchakin PN, Uchakina ON, et al. Antiviral activity of immunomodulator Selank in experimental influenza infection. Vopr Virusol. 2009;54(5):19-24. ↗